Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Vision Disorders

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    228 result(s) found for: Vision Disorders. Displaying page 1 of 12.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2012-005418-20 Sponsor Protocol Number: CRFB002G2302 Start Date*: 2013-07-03
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A 12-month, randomized, double-masked, sham-controlled, multicenter study to evaluate the efficacy and safety of 0.5 mg ranibizumab intravitreal injections in patients with visual impairment due ...
    Medical condition: Visual impairment due to vascular endothelial growth factor (VEGF) driven macular edema (ME)
    Disease: Version SOC Term Classification Code Term Level
    17.0 10015919 - Eye disorders 10025415 Macular oedema PT
    17.0 10015919 - Eye disorders 10047571 Visual impairment PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) IT (Completed) GB (Completed) LV (Completed) HU (Completed) CZ (Completed) IE (Completed) ES (Completed) BE (Completed) NL (Completed) DE (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2010-021662-30 Sponsor Protocol Number: CRFB002F2301 Start Date*: 2010-11-05
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A 12 month, phase III, randomized, double-masked, multi-center, active-controlled study to evaluate the efficacy and safety of two different dosing regimens of 0.5 mg ranibizumab vs. verteporfin PD...
    Medical condition: visual impairment due to choroidal neovascularization secondary to pathologic myopia
    Disease: Version SOC Term Classification Code Term Level
    12.1 10036803 Progressive high (degenerative) myopia LLT
    12.1 10060837 Choroidal neovascularization LLT
    12.1 10047571 Visual impairment LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PT (Completed) LV (Completed) HU (Completed) LT (Completed) FR (Completed) ES (Completed) IT (Completed) AT (Completed) SK (Completed) DE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2011-002350-31 Sponsor Protocol Number: CRFB002E2401 Start Date*: 2012-02-24
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A 24-month, phase IIIb, open-label, single arm, multicenter study assessing the efficacy and safety of an individualized, stabilization criteria-driven PRN dosing regimen with 0.5-mg ranibizumab in...
    Medical condition: visual impairment due to macular edema secondary to central retinal vein occlusion (CRVO)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10015919 - Eye disorders 10007972 Central retinal vein occlusion LLT
    14.1 10015919 - Eye disorders 10025415 Macular oedema PT
    14.1 10015919 - Eye disorders 10047571 Visual impairment PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) IE (Completed) SE (Completed) HU (Completed) AT (Completed) ES (Completed) CZ (Completed) SK (Completed) GR (Completed) PT (Completed) NL (Completed) PL (Completed) IT (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2011-002859-34 Sponsor Protocol Number: CRFB002E2402 Start Date*: 2012-04-20
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A 24-month, phase IIIb, open-label, randomized, activecontrolled, 3-arm, multicenter study assessing the efficacy and safety of an individualized, stabilization-criteria-driven PRN dosing regimen w...
    Medical condition: visual impairment due to macular edema secondary to branch retinal occlusion (BRVO)
    Disease: Version SOC Term Classification Code Term Level
    14.0 10015919 - Eye disorders 10025415 Macular oedema PT
    14.0 10015919 - Eye disorders 10038907 Retinal vein occlusion PT
    14.0 10015919 - Eye disorders 10047571 Visual impairment PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed) GB (Completed) SE (Completed) HU (Completed) CZ (Completed) ES (Completed) SK (Completed) GR (Completed) NL (Completed) PT (Completed) PL (Completed) FR (Completed) IT (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2011-001520-37 Sponsor Protocol Number: KETECT Start Date*: 2014-02-14
    Sponsor Name:Skåne University Hospital, Malmö
    Full Title: Ketamine as an alternative to electroconvulsive therapy for treatment of major depressive disorder
    Medical condition: Major depression disorder
    Disease: Version SOC Term Classification Code Term Level
    18.0 10037175 - Psychiatric disorders 10019063 Hallucination PT
    18.0 10015919 - Eye disorders 10013036 Diplopia PT
    18.0 100000004863 10061243 Post procedural nausea LLT
    18.0 10029205 - Nervous system disorders 10047343 Vertigo CNS origin PT
    18.0 10037175 - Psychiatric disorders 10015533 Euphoria LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-005417-38 Sponsor Protocol Number: CRFB002G2301 Start Date*: 2013-07-03
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A 12-month, randomized, double-masked, sham-controlled, multicenter study to evaluate the efficacy and safety of 0.5mg ranibizumab intravitreal injections in patients with visual impairment due to ...
    Medical condition: Visual impairment due to vascular endothelial growth factor (VEGF) driven choroidal neovascularization (CNV)
    Disease: Version SOC Term Classification Code Term Level
    17.0 10015919 - Eye disorders 10060837 Choroidal neovascularization LLT
    17.0 10015919 - Eye disorders 10047571 Visual impairment PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) IT (Completed) LV (Completed) PT (Completed) HU (Completed) CZ (Completed) ES (Completed) LT (Completed) BE (Completed) GR (Completed) DK (Completed) DE (Completed) PL (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2021-000183-29 Sponsor Protocol Number: REVISION Start Date*: 2022-03-09
    Sponsor Name:Eberhard-Karls University Tübingen, Med. Fac. rep. by University Hospital and its Commercial Director
    Full Title: Early Reperfusion Therapy with Intravenous Alteplase for Recovery of VISION in Acute Central Retinal Artery Occlusion (REVISION) - A double-blind randomized placebo-controlled phase III proof-of-co...
    Medical condition: Acute non-arteritic central retinal artery occlusion (CRAO)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10015919 - Eye disorders 10007971 Central retinal artery occlusion LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-000913-35 Sponsor Protocol Number: BECRO/OV/DORZO Start Date*: 2019-05-21
    Sponsor Name:BECRO (Cyprus) Ltd
    Full Title: A Randomized, Observer-blind, two Parallel Group, Multi-center, Clinical Trial for Comparing the Efficacy and Tolerability of Dorzo-Vision® sine Preservative-Free Eye Drops vs. Trusopt® Preservativ...
    Medical condition: Open angle glaucoma or ocular hypertension
    Disease: Version SOC Term Classification Code Term Level
    20.0 10015919 - Eye disorders 10015919 Eye disorders SOC
    20.0 10015919 - Eye disorders 10030348 Open angle glaucoma PT
    20.0 10015919 - Eye disorders 10030043 Ocular hypertension PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-002569-20 Sponsor Protocol Number: BIELEFELD-Janssen-PHRCN-2017 Start Date*: 2018-11-06
    Sponsor Name:CHU Dijon Bourgogne
    Full Title: A multicenter phase 2 single-arm proof-of-concept trial assessing the efficacy and safety of ustekinumab in association with prednisone, for the treatment of non-infectious severe uveitis (NISU)
    Medical condition:
    Disease: Version SOC Term Classification Code Term Level
    20.0 10015919 - Eye disorders 10046851 Uveitis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2011-003218-17 Sponsor Protocol Number: TRANEX1 Start Date*: 2012-11-08
    Sponsor Name:Hospital Universitario La Paz
    Full Title: Efficacy of topical tranexamic acid versus intravenous administration to reduce blood transfussion rate in total knee arthroplasty surgery: phase III, unicentric, controlled,double blind, randomiz...
    Medical condition: El sangrado perioperatorio es común en intervenciones quirúrgicas de ortopedia, especialmente en los reemplazos de rodilla con una estimación media de transfusión de concentrados de hematíes de un...
    Disease: Version SOC Term Classification Code Term Level
    15.0 10028395 - Musculoskeletal and connective tissue disorders 10033380 Pain back LLT
    15.0 10038738 - Respiratory, thoracic and mediastinal disorders 10052438 Paranasal sinus discomfort PT
    15.0 10021428 - Immune system disorders 10040562 Shock anaphylactic anaphylactoid LLT
    15.0 10017947 - Gastrointestinal disorders 10047700 Vomiting PT
    15.0 10017947 - Gastrointestinal disorders 10028813 Nausea PT
    15.0 10047065 - Vascular disorders 10066331 Arterial hypotension LLT
    15.0 10015919 - Eye disorders 10047514 Vision central defective LLT
    15.0 10029205 - Nervous system disorders 10051385 Drug-induced headache LLT
    15.0 10047065 - Vascular disorders 10043566 Thromboembolism LLT
    15.0 10015919 - Eye disorders 10047518 Vision disorders HLGT
    15.0 10017947 - Gastrointestinal disorders 10017947 Gastrointestinal disorders SOC
    15.0 10029205 - Nervous system disorders 10027606 Migraine type headaches LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2019-001493-28 Sponsor Protocol Number: OPA1 Start Date*: 2020-09-24
    Sponsor Name:Medizinische Universität Graz, Univ.-Augenklinik
    Full Title: Raxone® treatment for patients with dominant optic atrophy due to OPA1 gene mutation
    Medical condition: Autosomal dominant optic atrophy (ADOA)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10019895 Hereditary optic atrophy PT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2016-003497-40 Sponsor Protocol Number: NVG16E128 Start Date*: 2016-12-28
    Sponsor Name:SANTEN SAS
    Full Title: A PHASE IV, PROSPECTIVE, OPEN-LABEL, MULTICENTRE, SINGLE ARM, 3-MONTH PROOF OF CONCEPT STUDY TO ASSESS THE EFFECT OF IKERVIS® 1MG/ML (CICLOSPORIN) EYE DROPS ADMINISTERED ONCE DAILY ON THE QUALITY O...
    Medical condition: Effect of one eye drop of IKERVIS®on adult male or female (aged 18 years or above) Dry Eye Disease patients with severe keratitis despite the use of tear substitutes.
    Disease: Version SOC Term Classification Code Term Level
    19.1 10015919 - Eye disorders 10023332 Keratitis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2007-000583-25 Sponsor Protocol Number: 311523 Start Date*: 2008-05-23
    Sponsor Name:Bayer Schering Pharma AG
    Full Title: A randomized, double masked, active controlled, phase 3 study of the efficacy, safety, and tolerability of repeated doses of intravitreal VEGF Trap-Eye in subjects with neovascular age-related macu...
    Medical condition: Neovascular age-related macular degeneration (AMD)
    Disease: Version SOC Term Classification Code Term Level
    13.1 10015919 - Eye disorders 10064930 Age-related macular degeneration LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) NL (Completed) AT (Completed) BE (Completed) HU (Completed) CZ (Completed) SE (Completed) ES (Completed) FR (Completed) PT (Completed) LV (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2020-002255-37 Sponsor Protocol Number: MGT-RPGR-022 Start Date*: 2022-05-26
    Sponsor Name:MeiraGTx UK II Limited
    Full Title: Phase 3 Follow-up Study of AAV5-hRKp.RPGR for the Treatment of X-linked Retinitis Pigmentosa Associated with Variants in the RPGR gene
    Medical condition: X-Linked Retinitis Pigmentosa caused by mutations in the RPGR gene
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10038914 Retinitis pigmentosa PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: IE (Prematurely Ended) NL (Ongoing) BE (Ongoing) ES (Ongoing) FR (Ongoing) DK (Ongoing) DE (Prematurely Ended) IT (Ongoing) Outside EU/EEA
    Trial results: (No results available)
    EudraCT Number: 2010-023900-29 Sponsor Protocol Number: MAF-AGN-OPH-RET-004 Start Date*: 2011-08-23
    Sponsor Name:Allergan Pharmaceuticals Ireland
    Full Title: A 12-Month, Multicentre, Randomised, Parallel Group Study to Compare the Efficacy and Safety of Ozurdex® Versus Lucentis® in Patients with Branch Retinal Vein Occlusion
    Medical condition: Macula oedema secondary to branch retinal vein occlusion
    Disease: Version SOC Term Classification Code Term Level
    17.0 10015919 - Eye disorders 10025415 Macular oedema PT
    17.0 10015919 - Eye disorders 10038907 Retinal vein occlusion PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2011-003475-11 Sponsor Protocol Number: UCL/11/0083 Start Date*: 2011-11-15
    Sponsor Name:University College London (UCL)
    Full Title: A phase II double-blind, randomised, placebo-controlled trial of neuroprotection with phenytoin in acute optic neuritis
    Medical condition: Acute demyelinating optic neuritis
    Disease: Version SOC Term Classification Code Term Level
    16.0 10029205 - Nervous system disorders 10030942 Optic neuritis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2019-002503-17 Sponsor Protocol Number: 20170542 Start Date*: 2020-08-10
    Sponsor Name:Amgen Inc
    Full Title: A Randomized, Double-masked, Phase 3 Study of ABP 938 Efficacy and Safety Compared to Aflibercept (Eylea®) in Subjects with Neovascular Age-related Macular Degeneration
    Medical condition: Neovascular Age-related Macular Degeneration
    Disease: Version SOC Term Classification Code Term Level
    20.0 10015919 - Eye disorders 10071129 Neovascular age-related macular degeneration PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) LV (Completed) EE (Ongoing) SK (Completed) ES (Ongoing) CZ (Completed) LT (Ongoing) PL (Ongoing) IT (Ongoing)
    Trial results: View results
    EudraCT Number: 2014-005119-17 Sponsor Protocol Number: BAY86-5321/17850 Start Date*: 2015-05-07
    Sponsor Name:Bayer HealthCare AG
    Full Title: Open-label Phase-4 study to examine the change of vision-related quality of life in subjects with diabetic macular edema (DME) during treatment with intravitreal injections of 2 mg aflibercept acco...
    Medical condition: Diabetic macular edema (DME)
    Disease: Version SOC Term Classification Code Term Level
    18.0 10015919 - Eye disorders 10057934 Diabetic macular edema LLT
    18.0 10015919 - Eye disorders 10015919 Eye disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) CZ (Completed) SK (Completed) IT (Completed) LT (Completed) ES (Completed) PT (Completed) FR (Completed) DE (Completed) AT (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2020-000236-22 Sponsor Protocol Number: Study_protocol_CODEX-P_ver2_1 Start Date*: 2020-12-16
    Sponsor Name:Chronic Obstructive Pulmonary Disease Trial Network (COP:TRIN)
    Full Title: COPD EXacerbation and Pulmonary hypertension Trial - The effect of Sildenafil treatment to patients with COPD exacerbation and pulmonary hypertension
    Medical condition: This study will investigate treatment of patients with chronic obstructive pulmonary disease (COPD), who experience frequent exacerbations (AECOPD). Only patients with a minimum of 2 moderate AECOP...
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004854 10019203 Head spinning LLT
    20.1 100000004852 10033405 Pain head LLT
    20.0 100000004852 10019218 Headache NOS LLT
    20.1 100000004856 10000460 Acid dyspepsia LLT
    22.1 100000004856 10013947 Dyspepsia aggravated LLT
    20.0 100000004856 10013948 Dyspepsia and other specified disorders of function of stomach LLT
    21.1 100000004856 10019328 Heartburn-like dyspepsia LLT
    20.1 100000004856 10064536 Functional dyspepsia LLT
    23.1 100000004856 10012727 Diarrhea LLT
    20.0 100000004859 10023222 Joint pain LLT
    21.0 100000004859 10025012 Lumbo-sacral pain LLT
    21.1 100000004859 10028322 Muscle pain LLT
    20.0 100000004856 10033394 Pain epigastric LLT
    21.1 100000004866 10016046 Facial flushing LLT
    20.0 100000004853 10013614 Double vision LLT
    21.0 100000004848 10005604 Blood in urine LLT
    20.0 100000004872 10018801 Gynecomastia LLT
    20.0 100000004872 10060603 Hematospermia LLT
    20.0 100000004851 10002272 Anemia LLT
    22.1 100000004853 10034961 Photophobia aggravated LLT
    20.0 100000004871 10023139 Jaundice NOS LLT
    20.0 100000004853 10030042 Ocular hyperemia LLT
    20.1 100000004853 10051304 Retinal bleeding LLT
    20.1 100000004853 10005889 Blurry vision LLT
    20.1 100000004856 10046272 Upper abdominal pain LLT
    20.0 100000004856 10038263 Reflux oesophagitis LLT
    20.0 100000004856 10047706 Vomiting NOS LLT
    20.0 100000004867 10016558 Fever LLT
    21.1 100000004862 10024969 Lower respiratory tract infection NOS LLT
    20.0 100000004859 10048317 Myalgia aggravated LLT
    21.1 100000004859 10003990 Back pain (without radiation) LLT
    20.1 100000004852 10020922 Hypesthesia LLT
    20.0 100000004852 10027605 Migraine NOS LLT
    21.1 100000004852 10044572 Tremor limb LLT
    20.1 100000004852 10044570 Tremor finger LLT
    20.0 100000004873 10002856 Anxiety attack LLT
    20.0 100000004873 10022442 Insomnia NOS LLT
    20.0 100000004855 10011232 Coughing LLT
    20.0 100000004862 10040756 Sinusitis NOS LLT
    20.0 100000004867 10014210 Edema LLT
    20.0 100000004867 10014211 Edema (NOS) LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-004694-46 Sponsor Protocol Number: OPT-302-1005 Start Date*: 2021-08-06
    Sponsor Name:Opthea Limited
    Full Title: A Phase 3, Multicentre, Double-masked, Randomised Study to Evaluate the Efficacy and Safety of Intravitreal OPT-302 in Combination with Aflibercept, Compared with Aflibercept Alone, in Participants...
    Medical condition: Neovascular Age-related Macular Degeneration (wet AMD)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10015919 - Eye disorders 10015919 Eye disorders SOC
    27.0 10015919 - Eye disorders 10071129 Neovascular age-related macular degeneration PT
    20.1 10015919 - Eye disorders 10067791 Wet macular degeneration LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Ongoing) CZ (Ongoing) DE (Ongoing) LT (Ongoing) DK (Completed) LV (Ongoing) EE (Ongoing) NL (Ongoing) ES (Ongoing) BG (Ongoing) IT (Ongoing) HR (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 20 02:20:17 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA